[ad_1]
SOURCES:
Elaine Weiner, MD, assistant professor of psychiatry, University of Maryland Medical System.
Joshua Roffman, MD, assistant professor of psychiatry, Harvard Medical School; director, Brain Genomics Laboratory, Massachusetts General Hospital, Boston.
Thomas Milam, MD, chief medical officer, Iris Telehealth; associate professor of psychiatry, Virginia Tech Carilion School of Medicine & Research Institute.
Current Psychiatry: “Omega-3 fatty acids for psychiatric illness.”
Scientific Reports: “The association between neonatal vitamin D status and risk of schizophrenia.”
Journal of Clinical Endocrinology and Metabolism: “Serum vitamin D levels in relation to schizophrenia: a systematic review and meta-analysis of observational studies.”
BMC Trials: “Vitamin D supplementation compared to placebo in people with First Episode psychosis — Neuroprotection Design (DFEND): a protocol for a randomised, double-blind, placebo-controlled, parallel-group trial.”
Cambridge Core: “The effects of vitamin and mineral supplementation on symptoms of schizophrenia: a systematic review and meta-analysis.”
JAMA Psychiatry: “Randomized multicenter investigation of folate plus vitamin B12 supplementation in schizophrenia.”
Molecular Psychiatry: “Biochemical, physiologic, and clinical effects of L-methylfolate in schizophrenia: A randomized controlled trial.”
Cochrane Library: “Vitamin E for antipsychotic‐induced tardive dyskinesia.”
Brain, Behavior and Immunity: “Probiotic normalization of Candida albicans in schizophrenia: A randomized, placebo-controlled, longitudinal pilot study.”
BMC Psychiatry: “Clinical and metabolic response to vitamin D plus probiotic in schizophrenia patients.”
[ad_2]
Source link
